Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in
highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a
deceased donor, comparing desensitization using imlifidase with standard of care